Vol 31, No 2 (2024)
Original Article
Published online: 2022-10-27

open access

Page views 1257
Article views/downloads 421
Get Citation

Connect on Social Media

Connect on Social Media

Impaired coronary flow reserve in patients with poor type 2 diabetes control: Preliminary results from prospective microvascular dysfunction registry

Łukasz Niewiara12, Paweł Kleczyński13, Bartłomiej Guzik13, Piotr Szolc13, Jakub Baran13, Jakub Podolec13, Marta Diachyshyn1, Krzysztof Żmudka13, Jacek Legutko13
Pubmed: 36342032
Cardiol J 2024;31(2):185-192.

Abstract

Background: Type 2 diabetes (DM) is a common comorbidity associated with cardiovascular disease, especially when poor glucose control is present. Extracardiac microcirculatory complications prevalence is well documented, however coronary microcirculatory dysfunction (CMD) seem to be underreported in this group.

Methods: The present study analyzed coronary physiology measurements (coronary flow reserve [CFR], index of microcirculatory resistance [IMR], resistance reserve ratio [RRR]) in 47 diabetic patients (21 subjects with poor glycemia control defined as fasting glucose levels > 7.2 mmol/L and 26 with normal fasting glucose), and compared to 54 non-diabetic controls, who had undergone coronary angiography due to symptoms of chronic coronary syndrome. The median age of patients was 65.5 [59.0; 73.0] years old, 74% male, similar in terms of cardiovascular risk factors and prior myocardial infarction. Insulin was used by 19% of diabetic patients with poor glucose control and by 15% of those with DM and low fasting glucose.  

Results: Prevalence of CMD was 38% in poor glycemia control patients, 27% in DM-patients with proper glucose control and 31% of non-diabetics. Median CFR values were the lowest in poor DM control patients compared to both, normal fasting glucose (1.75 [1.37; 2.32] vs. 2.30 [1.75; 2.85], p = 0.026) and to non-diabetics (1.75 [1.37; 2.32] vs. 2.15 [1.50; 2.95], p = 0.045). Levels of IMR, RRR and MRR did not differ significantly between compared groups (p > 0.05 for all comparisons).

Conclusions: Poor glycemia control in type 2 DM might be associated with a higher prevalence of CMD driven by decreased coronary flow reserve, however, further research in larger groups of patients should be performed to confirm this observation.

Article available in PDF format

View PDF Download PDF file

References

  1. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2): 255–323.
  2. Nyström T, Holzmann MJ, Eliasson B, et al. Glycemic control in type 1 diabetes and long-term risk of cardiovascular events or death after coronary artery bypass grafting. J Am Coll Cardiol. 2015; 66(5): 535–543.
  3. Murthy VL, Naya M, Foster CR, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation. 2012; 126(15): 1858–1868.
  4. Vancheri F, Longo G, Vancheri S, et al. Coronary microvascular dysfunction. J Clin Med. 2020; 9(9).
  5. Leung M, Leung DY. Coronary microvascular function in patients with type 2 diabetes mellitus. EuroIntervention. 2016; 11(10): 1111–1117.
  6. Fearon WF, Balsam LB, Farouque HM, et al. Novel index for invasively assessing the coronary microcirculation. Circulation. 2003; 107(25): 3129–3132.
  7. Valensi P, Prévost G, Schnell O, et al. Targets for blood glucose: what have the trials told us. Eur J Prev Cardiol. 2019; 26(2_suppl): 64–72.
  8. Svanerud J, Ahn JM, Jeremias A, et al. Validation of a novel non-hyperaemic index of coronary artery stenosis severity: the Resting Full-cycle Ratio (VALIDATE RFR) study. EuroIntervention. 2018; 14(7): 806–814.
  9. Legutko J, Kleczyński P, Dziewierz A, et al. Comparison of hyperemic efficacy between femoral and antecubital fossa vein adenosine infusion for fractional flow reserve assessment. Postepy Kardiol Interwencyjnej. 2019; 15(1): 52–58.
  10. Legutko J, Kleczyński P, Dziewierz A, et al. Adenosine intracoronary bolus dose escalation versus intravenous infusion to induce maximum coronary hyperemia for fractional flow reserve assessment. Kardiol Pol. 2019; 77(6): 610–617.
  11. Lee JM, Layland J, Jung JH, et al. Integrated physiologic assessment of ischemic heart disease in real-world practice using index of microcirculatory resistance and fractional flow reserve: insights from the International Index of Microcirculatory Resistance Registry. Circ Cardiovasc Interv. 2015; 8(11): e002857.
  12. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477.
  13. Yong AS, Layland J, Fearon WF, et al. Calculation of the index of microcirculatory resistance without coronary wedge pressure measurement in the presence of epicardial stenosis. JACC Cardiovasc Interv. 2013; 6(1): 53–58.
  14. Layland J, Carrick D, McEntegart M, et al. Vasodilatory capacity of the coronary microcirculation is preserved in selected patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2013; 6(3): 231–236.
  15. De Bruyne B, Pijls NHJ, Gallinoro E, et al. Microvascular resistance reserve for Assessment of coronary microvascular function: JACC technology corner. J Am Coll Cardiol. 2021; 78(15): 1541–1549.
  16. Gallinoro E, Paolisso P, Candreva A, et al. Microvascular dysfunction in patients with type II diabetes mellitus: invasive assessment of absolute coronary blood flow and microvascular resistance reserve. Front Cardiovasc Med. 2021; 8: 765071.
  17. Osborne MT, Bajaj NS, Taqueti VR, et al. Coronary microvascular dysfunction identifies patients at high risk of adverse events across cardiometabolic diseases. J Am Coll Cardiol. 2017; 70(22): 2835–2837.
  18. Leung M, Leung DY. Coronary microvascular function in patients with type 2 diabetes mellitus. EuroIntervention. 2016; 11(10): 1111–1117.
  19. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24): 2545–2559.
  20. Turner R. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131): 837–853.
  21. Duckworth W, Abraira C, Moritz T. Glucose control and vascular complications in veterans with type 2 diabetes. J Vasc Surg. 2009; 360(2): 129–139.
  22. Lachin JM, Orchard TJ, Nathan DM. Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014; 37(1): 39–43.
  23. Nishi T, Saito Y, Kitahara H, et al. Coronary flow reserve and glycemic variability in patients with coronary artery disease. Intern Med. 2021; 60(8): 1151–1158.
  24. Sara JD, Taher R, Kolluri N, et al. Coronary microvascular dysfunction is associated with poor glycemic control amongst female diabetics with chest pain and non-obstructive coronary artery disease. Cardiovasc Diabetol. 2019; 18(1): 22.
  25. Neumann FJ, Sechtem U, Banning AP, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020.